Trial Profile

A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabiralizumab (Primary) ; Nivolumab (Primary) ; Sotigalimab (Primary)
Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions

03 Jul 2024 Status changed from active, no longer recruiting to completed.
23 Aug 2023 According to Pyxis Oncology, Inc media release, Apexigen has been acquired by Pyxis Oncology
22 Jul 2022 Planned End Date changed from 1 Oct 2024 to 1 Oct 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com